Literature DB >> 10944743

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

A Clegg1, J Bryant, R Milne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10944743

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  9 in total

1.  Drug treatment of multiple sclerosis. Clinical review was unsystematic.

Authors:  R Milne; A Clegg; J Bryant
Journal:  BMJ       Date:  2001-02-03

2.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

Review 3.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?

Authors:  P V Mohan; W Tarnow-Mordi; B Stenson; P Brocklehurst; K Haque; V Cavendish; A Cust
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

4.  Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis.

Authors:  M Etemadifar; M Janghorbani; V Shaygannejad
Journal:  J Neurol       Date:  2007-12-14       Impact factor: 4.849

Review 5.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Assessing cost-effectiveness in the management of multiple sclerosis.

Authors:  Ceri J Phillips; Ioan Humphreys
Journal:  Clinicoecon Outcomes Res       Date:  2009-11-18

7.  Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.

Authors:  Luca Massacesi; Irene Tramacere; Salvatore Amoroso; Mario A Battaglia; Maria Donata Benedetti; Graziella Filippini; Loredana La Mantia; Anna Repice; Alessandra Solari; Gioacchino Tedeschi; Clara Milanese
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

8.  Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.

Authors:  Alireza Olyaeemanesh; Mahbobeh Rahmani; Reza Goudarzi; Abulghasem Rahimdel
Journal:  Med J Islam Repub Iran       Date:  2016-02-23

9.  Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.

Authors:  David Yamamoto; Jonathan D Campbell
Journal:  Autoimmune Dis       Date:  2012-12-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.